2.34
price down icon2.90%   -0.07
after-market Handel nachbörslich: 2.33 -0.010 -0.43%
loading

Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten

pulisher
Aug 14, 2025

Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewswire

Aug 14, 2025
pulisher
Aug 14, 2025

Elliott Wave Theory Predicts Pullback in Cassava Sciences Inc.2025 Trade Ideas & Daily Growth Stock Tips - thegnnews.com

Aug 14, 2025
pulisher
Aug 14, 2025

Is Cassava Sciences Inc. Starting a New Uptrend2025 Biggest Moves & Daily Profit Maximizing Trade Tips - thegnnews.com

Aug 14, 2025
pulisher
Aug 14, 2025

CASSAVA SCIENCES INC SEC 10-Q Report - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Cassava Sciences Posts Q2 Loss on Pivot - Nasdaq

Aug 14, 2025
pulisher
Aug 14, 2025

Cassava Sciences Advances Simufilam Development for TSC-Related Epilepsy and Reports Financial Results for Q2 2025 - Quiver Quantitative

Aug 14, 2025
pulisher
Aug 12, 2025

Why is Cassava Sciences Inc. Equity Warrant stock going downTop Earnings Growth Momentum Picks - thegnnews.com

Aug 12, 2025
pulisher
Aug 12, 2025

Why Cassava Sciences Inc. Equity Warrant stock attracts strong analyst attentionTrend Following High Return Picks - thegnnews.com

Aug 12, 2025
pulisher
Aug 08, 2025

Cassava Sciences Inc. Equity Warrant Stages Intraday Comeback — Trend ChangeValue Investing Picks With Stability Outlined - beatles.ru

Aug 08, 2025
pulisher
Aug 08, 2025

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewswire

Aug 08, 2025
pulisher
Aug 07, 2025

Cassava Sciences Boosts Medical Leadership with New CMO Appointment, Analysts Maintain Cautionary Price Target - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Cassava Sciences appoints Hulihan as Chief Medical Officer - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Cassava Sciences appoints Dr. Joseph Hulihan as Chief Medical Officer - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Cassava Sciences' Strategic Hire of Joe Hulihan as CMO: A Catalyst for Accelerated Pipeline Development in Neurodegenerative Therapeutics - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Cassava Sciences appoints Joseph Hulihan as chief medical officer By Investing.com - Investing.com South Africa

Aug 07, 2025
pulisher
Aug 07, 2025

Former J&J Executive Joins Cassava Sciences to Lead Breakthrough Epilepsy Drug Development - Stock Titan

Aug 07, 2025
pulisher
Aug 05, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire

Aug 05, 2025
pulisher
Aug 04, 2025

Simufilam reduces tuberous sclerosis-associated seizures - BioWorld MedTech

Aug 04, 2025
pulisher
Aug 04, 2025

Cassava Sciences Announces Positive Preclinical Results - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam For Tsc-Related Epilepsy - TradingView

Aug 04, 2025
pulisher
Aug 04, 2025

SAVA’s simufilam cuts seizures in TSC mice; first human trial slated H1 2026 | SAVA SEC FilingForm 8-K - Stock Titan

Aug 04, 2025
pulisher
Aug 04, 2025

Cassava Sciences Reports Positive Preclinical Results for Simufilam in Tuberous Sclerosis Complex-Related Epilepsy - Quiver Quantitative

Aug 04, 2025
pulisher
Aug 04, 2025

Cassava Sciences and Simufilam: A Groundbreaking Opportunity in TSC-Related Epilepsy - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - The Manila Times

Aug 04, 2025
pulisher
Aug 03, 2025

What analysts say about Cassava Sciences Inc. Equity Warrant stockInvest like a pro with expert recommendations - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Cassava Sciences Inc. stockTremendous growth opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Cassava Sciences Inc. stock attracting strong analyst attentionUncover the best stocks for explosive growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Cassava Sciences Inc. stock overvalued or undervaluedMaximize your returns with portfolio optimization - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Cassava Sciences Inc. stock higher in 2025Consistently high returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Cassava Sciences Inc. Equity Warrant Stock Analysis and ForecastTremendous gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Cassava Sciences Inc. stockPhenomenal capital gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the technical indicators suggesting about Cassava Sciences Inc. Equity WarrantFree Trading Strategy Suggestions - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Cassava Sciences Inc. Equity Warrant stockSuperior stock selection - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Cassava Sciences Inc. Equity Warrant stock overvalued or undervaluedMaximize your portfolio’s growth potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Cassava Sciences Inc. stockUnlock exclusive stock market forecasts - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Cassava Sciences Inc. Equity Warrant stock price move sharplyExponential wealth increase - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Cassava Sciences Inc. compare to its industry peersHigh-profit stock alerts - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Cassava Sciences Inc. generate profit in a changing economyExponentially increasing returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Cassava Sciences Inc. Equity Warrant stock in 2025Maximize returns with smart investment plans - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What drives Cassava Sciences Inc. Equity Warrant stock priceMarket-leading capital gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Cassava Sciences Inc. in the next 12 monthsExceptional profit margins - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Cassava Sciences Inc. Equity Warrant in the next 12 monthsCapitalize on emerging market opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is Cassava Sciences Inc. Equity Warrant company’s growth strategyMaximize returns with effective portfolio management - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Cassava Sciences Inc. Equity Warrant stock attracting strong analyst attentionExceptional trading performance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Cassava Sciences Inc. Equity Warrant stock higher in 2025Unstoppable profit momentum - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Cassava Sciences Inc. Equity Warrant stock expected to show significant growthTremendous return rates - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is Cassava Sciences Inc. company’s balance sheetInvest smarter with high-probability setups - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What institutional investors are buying Cassava Sciences Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What analysts say about Cassava Sciences Inc. stockHigh-profit capital plays - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Cassava Sciences, Inc. to Contact the Firm Today! - ACCESS Newswire

Aug 02, 2025
pulisher
Aug 02, 2025

What is Cassava Sciences Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

Should I hold or sell Cassava Sciences Inc. stock in 2025Smart Portfolio Strategy With High Returns - Jammu Links News

Aug 01, 2025
$36.35
price down icon 0.41%
$86.92
price up icon 0.88%
$26.69
price up icon 0.91%
$127.80
price up icon 0.04%
$113.52
price up icon 0.73%
biotechnology ONC
$321.36
price up icon 3.77%
Kapitalisierung:     |  Volumen (24h):